Graft Versus Host Disease (GVHD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500
Buy Report

Published: June 30, 2022 Report Code: GDGMDHC22212IDB-ST

Select Item

Graft Versus Host Disease Pipeline Drugs Market Report Overview

Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient’s body. Symptoms include abdominal pain or cramps, nausea, vomiting, diarrhea, dry or irritated eyes, jaundice, shortness of breath, vaginal dryness, and weight loss. Treatment includes immunosuppressants.

The GVHD pipeline market research report provides comprehensive information on the therapeutics under development for GVHD, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for GVHD and features dormant and discontinued projects.

Key Targets Tyrosine Protein Kinase JAK1, Tyrosine Protein Kinase JAK2, Tyrosine Protein Kinase BTK, Interleukin 2 Receptor, Programmed Cell Death Protein 1, Alpha 1 Antitrypsin, Cells Expressing B Lymphocyte Antigen CD20, Interleukin 2 Receptor Subunit Beta, Macrophage Colony Stimulating Factor 1 Receptor, and Rho Associated Protein Kinase 2
Key Mechanisms of Action Tyrosine Protein Kinase JAK1 Inhibitor, Tyrosine Protein Kinase JAK2 Inhibitor, Tyrosine Protein Kinase BTK Inhibitor, Interleukin 2 Receptor Agonist, Alpha 1 Antitrypsin Replacement, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, Interleukin 2 Receptor Subunit Beta Antagonist, and Programmed Cell Death Protein 1 Agonist
Key Routes of Administration Intravenous, Oral, Subcutaneous, Parenteral, Topical, Intracoronary, Intramuscular, and Hemodialysis
Key Molecule Type Small Molecule, Cell Therapy, Monoclonal Antibody, Biologic, Fusion Protein, Recombinant Protein, Gene-Modified Cell Therapy, Antibody, and Blood Derivative.
Major Companies Incyte Corp, Bristol-Myers Squibb Co, Kadmon Holdings Inc, Mesoblast Ltd, Ossium Health Inc, Pfizer Inc, AbbVie Inc, and AnaptysBio Inc.
Major Universities H. Lee Moffitt Cancer Center & Research Institute Inc, Cincinnati Children’s Hospital Medical Center, Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Emory University, Fraunhofer Institute for Cell Therapy and Immunology, and French National Institute of Health and Medical Research

Key Targets in the GVHD Pipeline Products Market

The key targets in the GVHD pipeline products market are Tyrosine Protein Kinase JAK1, Tyrosine Protein Kinase JAK2, Tyrosine Protein Kinase BTK, Interleukin 2 Receptor, Programmed Cell Death Protein 1, Alpha 1 Antitrypsin, Cells Expressing B Lymphocyte Antigen CD20, Interleukin 2 Receptor Subunit Beta, Macrophage Colony Stimulating Factor 1 Receptor, and Rho Associated Protein Kinase 2.

GVHD Pipeline Products Market Analysis by Targets

GVHD Pipeline Products Market Analysis by Targets

For more target insights, download a free report sample

Key Mechanisms of Action in the GVHD Pipeline Products Market

The key mechanisms of action in the graft versus host disease (GVHD) pipeline products market are Tyrosine Protein Kinase JAK1 Inhibitor, Tyrosine Protein Kinase JAK2 Inhibitor, Tyrosine Protein Kinase BTK Inhibitor, Interleukin 2 Receptor Agonist, Alpha 1 Antitrypsin Replacement, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, Interleukin 2 Receptor Subunit Beta Antagonist, and Programmed Cell Death Protein 1 Agonist.

GVHD Pipeline Products Market Analysis by Mechanisms of Action

GVHD Pipeline Products Market Analysis by Mechanisms of Action

For more mechanisms of action insights, download a free report sample

Key Routes of Administration in the GVHD Pipeline Products Market

The key routes of administration in the graft versus host disease pipeline products market are intravenous, oral, subcutaneous, parenteral, topical, intracoronary, intramuscular, and hemodialysis.

GVHD Pipeline Products Market Analysis by Routes of Administration

GVHD Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights, download a free report sample

Key Molecule Types in the GVHD Pipeline Products Market

The key molecule types in the GVHD pipeline products market are small molecule, cell therapy, monoclonal antibody, biologic, fusion protein, recombinant protein, gene-modified cell therapy, antibody, and blood derivative.

GVHD Pipeline Products Market Analysis by Molecule Types

GVHD Pipeline Products Market Analysis by Molecule Types

For more molecule-type insights, download a free report sample

Key Companies in the GVHD Pipeline Products Market

Some of the major companies in the Graft Versus Host Disease Pipeline Drugs Market pipeline products market are Incyte Corp, Bristol-Myers Squibb Co, Kadmon Holdings Inc, Mesoblast Ltd, Ossium Health Inc, Pfizer Inc, AbbVie Inc, and AnaptysBio Inc.

AbbVie Inc: AbbVie Inc (AbbVie) is a specialty biopharmaceutical company that discovers, develops, manufactures, and commercializes drugs for the treatment of chronic and complex diseases. Its pharmaceuticals are indicated for the treatment of metabolic diseases, rheumatological diseases, neurological disorders, viral diseases, skin diseases, complications associated with cystic fibrosis, pain related to endometriosis, diseases of the gastrointestinal tract, various cancer types, and other serious health conditions. AbbVie is also advancing its pipeline programs for the treatment of cystic fibrosis, Women’s Health, various cancers, neurological disorders, and other autoimmune diseases. The company markets its products directly to wholesalers, distributors, healthcare facilities, government agencies, specialty pharmacies, and independent retailers through its distribution centers and public warehouses across the world. AbbVie is headquartered in North Chicago, Illinois, the US.

GVHD Pipeline Products Market Analysis by Companies

GVHD Pipeline Products Market Analysis by Companies

For more company insights, download a free report sample

Key Universities in the GVHD Pipeline Products Market

Some of the key universities in the GVHD pipeline products market are H. Lee Moffitt Cancer Center & Research Institute Inc, Cincinnati Children’s Hospital Medical Center, Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Emory University, Fraunhofer Institute for Cell Therapy and Immunology, and French National Institute of Health and Medical Research.

GVHD Pipeline Products Market Analysis by Universities

GVHD Pipeline Products Market Analysis by Universities

For more university insights, download a free report sample

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of GVHD (Central Nervous System).

  • The pipeline guide reviews pipeline therapeutics for GVHD (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in GVHD (Central Nervous System) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates GVHD (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews the latest news related to pipeline therapeutics for GVHD (Central Nervous System)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for GVHD (Central Nervous System).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding GVHD (Central Nervous System) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

9 Meters Biopharma Inc
Abbisko Cayman Limited
AbbVie Inc
Accro BioScience (Suzhou) Co Ltd
Actitrexx GmbH
Adienne Pharma & Biotech SA
Alphamab Oncology
AltruBio Inc
Amcyte Pharma Inc
Amgen Inc
AnaMar AB
AnaptysBio Inc
ASC Therapeutics Inc
AstraZeneca Plc
Athos Therapeutics Inc
Autolus Therapeutics Plc
Avalon GloboCare Corp
Bellicum Pharmaceuticals Inc
Biocon Ltd
Biogen Inc
BioIncept LLC
BlueRock Therapeutics LLC
BlueSphere Bio Inc
Boryung ViGenCell Inc
Bristol-Myers Squibb Co
Capricor Therapeutics Inc
Cellective BioTherapy Inc
Cellenkos Inc
Cellestia Biotech AG
Cellix Bio Pvt Ltd
CELLnLIFE Inc
Celltrion Inc
Cellvation Inc
CheckPoint Immunology Inc
Claritas Pharmaceuticals Inc
Clinigen Ltd
Connext Co Ltd
Corvus Pharmaceuticals Inc
CSL Ltd
CTI BioPharma Corp
Cue Biopharma Inc
Cynata Therapeutics Ltd
Cytopeutics Pte Ltd
Daewoong Pharmaceutical Co Ltd
Dianomi Therapeutics Inc
Dualogics Corp
Educell doo
Eli Lilly and Co
enGene Inc
Equillium Inc
EV Therapeutics Inc
Evive Biotech
ExCellThera Inc
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Forte Biosciences Inc
Genentech USA Inc
Glia LLC
Good T Cells Inc
Grifols SA
GSK plc
Hangzhou East China Pharmaceutical Group Co Ltd
Humanigen Inc
iCELL Biotechnology Co Ltd
Immplacate Inc
Immune Modulation Inc
ImmuneTarget Inc
Imstem Biotechnology Inc
Incyte Corp
Inmagene Biopharmaceuticals Ltd
Jazz Pharmaceuticals Plc
JN Biosciences LLC
Kadmon Holdings Inc
Kamada Pharmaceuticals
Kiniksa Pharmaceuticals Ltd
Kymab Ltd
MaaT Pharma
Machavert Pharmaceuticals LLC
Magenta Therapeutics Inc
Mallinckrodt Plc
Medexus Pharmaceuticals Inc
Medicenna Therapeutics Corp
Mediolanum farmaceutici SpA
Medsenic SAS
Merck & Co Inc
Mereo Biopharma Group Plc
Mesoblast Ltd
Millennium Pharmaceuticals Inc
MiNK Therapeutics Inc
MitoImmune Therapeutics Inc
Moderna Inc
NapaJen Pharma Inc
Neoleukin Therapeutics Inc
Neovii Pharmaceuticals AG
Nurix Therapeutics Inc
OncoC4 Inc
Orca Biosystems Inc
OSE Immunotherapeutics SA
Ossium Health Inc
Panorama Researchama Research
Pfizer Inc
Platinum Biotech (Beijing) Co Ltd
Pluristem Therapeutics Inc
Precision Biosciences Inc
Rebus Holdings Inc
REGiMMUNE Corp
Rheos Medicines Inc
Sanofi
SCM lifescience Co Ltd
Seagen Inc
Secura Bio Inc
Seres Therapeutics Inc
Shenzhen Chipscreen Biosciences Co Ltd
Sino Biopharmaceutical Ltd
Sorrento Therapeutics Inc
STERO Biotechs Ltd
StingInn LLC
Suzhou Connect Biopharmaceuticals Ltd
Suzhou Regend Therapeutics Co Ltd
Suzhou Zelgen Biopharmaceutical Co Ltd
Syndax Pharmaceuticals Inc
Synthetic Biologics Inc
Takeda Pharmaceutical Co Ltd
Targazyme Inc
TCF GmbH
TCR2 Therapeutics Inc
TeraImmune Inc
Tianjin Angsai Cell Genetic Engineering Co Ltd
TreeFrog Therapeutics SAS
Triursus Therapeutics Inc
United BioPharma Inc
Vault Pharma Inc
VectivBio Holding AG
Vedanta Biosciences Inc
Viracta Therapeutics Inc
Visterra Inc
VITRAC Therapeutics LLC
Xbiome Co Ltd
Xenikos BV
Xenothera SAS

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Graft Versus Host Disease (GVHD) – Overview

Graft Versus Host Disease (GVHD) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Graft Versus Host Disease (GVHD) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Graft Versus Host Disease (GVHD) – Companies Involved in Therapeutics Development

Graft Versus Host Disease (GVHD) – Drug Profiles

Graft Versus Host Disease (GVHD) – Dormant Projects

Graft Versus Host Disease (GVHD) – Discontinued Products

Graft Versus Host Disease (GVHD) – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Frequently asked questions

  • What are the key targets in the GVHD pipeline products market?

    The key targets in the GVHD pipeline products market are Tyrosine Protein Kinase JAK1, Tyrosine Protein Kinase JAK2, Tyrosine Protein Kinase BTK, Interleukin 2 Receptor, Programmed Cell Death Protein 1, Alpha 1 Antitrypsin, Cells Expressing B Lymphocyte Antigen CD20, Interleukin 2 Receptor Subunit Beta, Macrophage Colony Stimulating Factor 1 Receptor, and Rho Associated Protein Kinase 2.

  • What are the key mechanisms of action in the GVHD pipeline products market?

    The key mechanisms of action in the GVHD pipeline products market are Tyrosine Protein Kinase JAK1 Inhibitor, Tyrosine Protein Kinase JAK2 Inhibitor, Tyrosine Protein Kinase BTK Inhibitor, Interleukin 2 Receptor Agonist, Alpha 1 Antitrypsin Replacement, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, Interleukin 2 Receptor Subunit Beta Antagonist, and Programmed Cell Death Protein 1 Agonist.

  • What are the key routes of administration in the GVHD pipeline products market?

    The key routes of administration in the GVHD pipeline products market are intravenous, oral, subcutaneous, parenteral, topical, intracoronary, intramuscular, and hemodialysis.

  • What are the key molecule types in the GVHD pipeline products market?

    The key molecule types in the GVHD pipeline products market are small molecule, small molecule, cell therapy, monoclonal antibody, biologic, fusion protein, recombinant protein, gene-modified cell therapy, antibody, and blood derivative.

  • Which are the major companies in the GVHD pipeline products market?

    Some of the major companies in the GVHD pipeline products market are Incyte Corp, Bristol-Myers Squibb Co, Kadmon Holdings Inc, Mesoblast Ltd, Ossium Health Inc, Pfizer Inc, AbbVie Inc, and AnaptysBio Inc.

  • Which are the major universities in the GVHD pipeline products market?

    Some of the major universities in the GVHD pipeline products market are H. Lee Moffitt Cancer Center & Research Institute Inc, Cincinnati Children’s Hospital Medical Center, Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Emory University, Fraunhofer Institute for Cell Therapy and Immunology, and French National Institute of Health and Medical Research.

Graft Versus Host Disease (GVHD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,500

Can be used by individual purchaser only

Most Popular
$5,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Immunology reports
Pharmaceuticals
New
Innovation in pharma: transdermal drug delivery
$250 | November 2023
Pharmaceuticals
New
Innovation in Pharmaceuticals: Platinum as active pharmaceutical ingredient
$250 | November 2023
Pharmaceuticals
New
Synthetic Biology - Thematic Intelligence
$995 | November 2023
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Graft Versus Host Disease (GVHD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Graft Versus Host Disease (GVHD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more